Moreover, up-regulation of AURKA/PLK/CDK1 contributes to PI3K inhibitor resistance in glioblastoma [67], and AURKA drives the evolution of resistance to EGFR inhibitor in lung cancer [31]. Here, PLK1 is linked to lung cancer.